Ricklie A. Julian
Expertise in
13
conditions

Dr. Ricklie A. Julian

Otolaryngology | Oncology
3838 North Campbell Avenue, Building 1, 
Tucson, AZ 
Accepting New Patients
Offers Telehealth
Referral may be required
Before you request
Expertise in
13
conditions
3838 North Campbell Avenue, Building 1, 
Tucson, AZ 

Overview

My research and clinical interests focus on the development of novel treatments for patients with lung and head and neck malignancies.

Dr. Julian is highly rated in 13 conditions, according to our data. Her clinical expertise encompasses Glioma, Pleuropulmonary Blastoma, Ewing Sarcoma, and Head and Neck Squamous Cell Carcinoma (HNSCC).

Dr. Julian is board certified in American Board Of Internal Medicine/Medical Oncology, American Board Of Internal Medicine, and American Board Of Internal Medicine/Hematology. She is actively involved in clinical research, co-authoring 10 peer reviewed articles and participating in 8 clinical trials. Dr. Julian is currently accepting new patients.

Specialties

Otolaryngology
Oncology

Licenses

Internal Medicine in AZ

Board Certifications

American Board Of Internal Medicine/Medical Oncology
American Board Of Internal Medicine
American Board Of Internal Medicine/Hematology

Fellowships

NYU Medical Center, Hematology/Oncology, 2019

Hospital Affiliations

Banner - University Medical Center Tucson
Banner - University Medical Center South
Banner - University Medical Center Tucson Campus
Banner-University Medical Center South Campus

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Group Health Cooperative
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
VibrantRx
  • MEDICARE PDP
  • OTHER MEDICARE
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 13 Less Insurance Carriers -

Locations

University of Arizona Cancer Center
3838 North Campbell Avenue, Building 1, Tucson, AZ 85719
Other Locations
University of Arizona Cancer Center
1891 West Orange Grove Road, Building 1, Tucson, AZ 85704

Additional Areas of Focus

Dr. Julian has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Lung Cancer

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC
Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2026
Intervention Type: Drug, Biological
Study Drugs: Carboplatin, Cisplatin, Durvalumab, Etoposide, Paclitaxel, Pemetrexed Disodium
Study Phase: Phase 3
Randomized Phase II/III Trial of Adjuvant Radiation Therapy With Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck
Randomized Phase II/III Trial of Adjuvant Radiation Therapy With Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck
Enrollment Status: Suspended
Publish Date: September 01, 2026
Intervention Type: Procedure, Drug, Other, Radiation, Biological
Study Drugs: Atezolizumab, Cetuximab, Cisplatin, Docetaxel
Study Phase: Phase 2/Phase 3
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Enrollment Status: Active_not_recruiting
Publish Date: August 27, 2026
Intervention Type: Other, Drug, Radiation, Procedure
Study Drugs: Atezolizumab, Carboplatin, Cisplatin, Etoposide
Study Phase: Phase 3
Phase I Trial With Expansion Cohort of DNA-PK Inhibition and IMRT in Cisplatin-Ineligible Patients With Stage 3-4 Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)
Phase I Trial With Expansion Cohort of DNA-PK Inhibition and IMRT in Cisplatin-Ineligible Patients With Stage 3-4 Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2026
Intervention Type: Drug, Procedure, Radiation, Other
Study Drug: Peposertib
Study Phase: Phase 1
Phase II Randomized Trial of Avelumab Plus Cetuximab Versus Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma of the Skin (cSCC)
Phase II Randomized Trial of Avelumab Plus Cetuximab Versus Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma of the Skin (cSCC)
Enrollment Status: Active_not_recruiting
Publish Date: June 02, 2026
Intervention Type: Drug
Study Drugs: Avelumab, Cetuximab
Study Phase: Phase 2
Immune Modulation by Abemaciclib in HPV-Negative Head and Neck Squamous Cell Carcinoma (HNSCC): A Phase II Window Trial.
Immune Modulation by Abemaciclib in HPV-Negative Head and Neck Squamous Cell Carcinoma (HNSCC): A Phase II Window Trial.
Enrollment Status: Terminated
Publish Date: May 22, 2026
Intervention Type: Drug
Study Drug: Abemaciclib
Study Phase: Phase 2
Phase II Randomized Trial of Radiotherapy With Concurrent and Adjuvant Pembrolizumab (Keytruda®) Versus Concurrent Chemotherapy in Patients With Advanced/Intermediate-Risk p16+ Head and Neck Squamous Cell Carcinoma (KEYCHAIN)
Phase II Randomized Trial of Radiotherapy With Concurrent and Adjuvant Pembrolizumab (Keytruda®) Versus Concurrent Chemotherapy in Patients With Advanced/Intermediate-Risk p16+ Head and Neck Squamous Cell Carcinoma (KEYCHAIN)
Enrollment Status: Active_not_recruiting
Publish Date: October 07, 2025
Intervention Type: Drug, Radiation
Study Drugs: Pembrolizumab, Cisplatin
Study Phase: Phase 2
Biomarker Modulation by Alpelisib (BYL719) in Transorally Resectable, HPV-Associated HNSCC: A Phase II Window Trial
Biomarker Modulation by Alpelisib (BYL719) in Transorally Resectable, HPV-Associated HNSCC: A Phase II Window Trial
Enrollment Status: Terminated
Publish Date: April 17, 2024
Intervention Type: Other, Drug, Procedure
Study Drug: Alpelisib
Study Phase: Phase 2
View 7 Less Clinical Trials

10 Total Publications

Phase 1 open-label study of ASP9801, an oncolytic virus, in patients with advanced or metastatic solid tumors.
Phase 1 open-label study of ASP9801, an oncolytic virus, in patients with advanced or metastatic solid tumors.
Journal: Journal for immunotherapy of cancer
Published: November 13, 2025
Similar Doctors
Expertise in
11
conditions
Expertise in
11
conditions
Referral may be required
Before you request

Banner-University Medical Center Tucson Campus

1625 North Campbell Avenue, 
Tucson, AZ 
 (0.3 miles away)
520-694-0111
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

I enjoy traveling, dancing and food. Dr. Shroff is highly rated in 11 conditions, according to our data. Her clinical expertise encompasses Cholangiocarcinoma (Bile Duct Cancer), Pancreatic Cancer, Gallbladder Cancer, Pancreaticoduodenectomy, and Pancreatectomy. Dr. Shroff is board certified in American Board Of Internal Medicine/Medical Oncology. Dr. Shroff is currently accepting new patients.

Expertise in
25
conditions
Expertise in
25
conditions
Referral may be required
Before you request

University Of Arizona Cancer Center

3838 North Campbell Avenue, Building 1, 
Tucson, AZ 
 (0.1 miles away)
520-694-2873
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Linda Garland is an Oncologist practicing medicine in Tucson, Arizona. Dr. Garland is highly rated in 25 conditions, according to our data. Her clinical expertise encompasses Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), and Pleuropulmonary Blastoma. Dr. Garland is board certified in American Board Of Internal Medicine/Medical Oncology. Dr. Garland is currently accepting new patients.

Expertise in
17
conditions
Expertise in
17
conditions
Referral may be required
Before you request

University Of Arizona Cancer Center

3838 North Campbell Avenue, Building 1, 
Tucson, AZ 
 (0.1 miles away)
520-694-2873
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

I enjoy advancing medicine through academics and excellent patient care.My particular interests are in clinical trial development and laboratory research investigating new agents to improve outcomes in patients with GI cancers. Dr. Scott is highly rated in 17 conditions, according to our data. His clinical expertise encompasses Colorectal Cancer, Pancreatic Cancer, Lynch Syndrome, Neuroendocrine Tumor, and Bone Marrow Aspiration. Dr. Scott is board certified in American Board Of Internal Medicine/Medical Oncology and American Board Of Internal Medicine. Dr. Scott is currently accepting new patients.

Frequently Asked Questions about Dr. Ricklie A. Julian

How do I make an appointment with Dr. Ricklie A. Julian?

You can book an appointment with Dr. Ricklie A. Julian by calling their office at 520-694-2873. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Ricklie A. Julian a top-rated expert for Glioma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Ricklie A. Julian is classified as an Advanced expert for Glioma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Ricklie A. Julian specialize in?

While Dr. Ricklie A. Julian is a Otolaryngology, they have specific expertise in Glioma, Pleuropulmonary Blastoma, and Ewing Sarcoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Otolaryngology.

Does Dr. Ricklie A. Julian participate in research or clinical trials?

Yes. Dr. Ricklie A. Julian has published 10 articles and abstracts on conditions like Glioma. You can view a list of Dr. Ricklie A. Julian's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Ricklie A. Julian accept my insurance?

Dr. Ricklie A. Julian accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 520-694-2873 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Julian's expertise for a condition
ConditionClose
      View All 13 Advanced Conditions
      View All 22 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile